Mifepristone complications less than one percent?

That’s not what the data really show By Randall K. O’Bannon, Ph.D. NRL Director of Education & Research In the recent hearing at the U.S. Fifth Circuit Court on the U.S. Food and Drug Administration’s approval the abortion pill mifepristone, government lawyer Sarah Harrington claimed that “the rate of serious complications is well less than …

Continue reading "Mifepristone complications less than one percent?"

Abortion Myths That Need Dismantling: Six Week Bans Take Effect Before Many Women Know They’re Pregnant

By Randall K. O’Bannon, Ph.D., NRL Director of Education & Research It is hard to tell exactly when or where the first statement was made, but shortly after pro-lifers introduced the first “Heartbeat Bill” in 2011, pro-abortion activists began complaining that the law, if passed, would ban abortions as early as the sixth week of …

Continue reading "Abortion Myths That Need Dismantling: Six Week Bans Take Effect Before Many Women Know They’re Pregnant"

How do you respond to those who say that taking mifepristone is “safer than taking Tylenol”?

Editor’s note. Chemical abortions [“medication abortions”] now account for the deaths of over 50% of the babies lost to abortion. There are many reasons for the huge increase but likely at the top is the blatant lie that “medication abortions” are “safe” and, indeed, “safer than taking Tylenol.” We asked Dr. Randall K. O’Bannon, NRLC’s Director …

Continue reading "How do you respond to those who say that taking mifepristone is “safer than taking Tylenol”?"

Annual Report Shows Planned Parenthood “Relentless” in Abortion Push “Non-profit” records record revenues

By Randall K. O’Bannon, Ph.D., NRL Director of Education & Research To pro-lifers, the overturning of Roe was one of the best things that ever happened to this country. To Planned Parenthood, it was the worst.  The opening text of the inside cover of Planned Parenthood’s 2021-2022 Annual Report says it directly: If it wasn’t clear from …

Continue reading "Annual Report Shows Planned Parenthood “Relentless” in Abortion Push “Non-profit” records record revenues"

What to make of all the talk about using misoprostol alone for abortion if mifepristone is limited

By Randall K. O’Bannon, NRL Director of Education & Research Editor’s note. It’s uncanny how well Dr. O’Bannon anticipated what the Abortion Industry and its friends in the media would say about the “abortion pill.” This ran last Friday. Today, Niha Masih of the Washington Post conceded misoprostol used alone was less effective and “can be more painful and …

Continue reading "What to make of all the talk about using misoprostol alone for abortion if mifepristone is limited"

Addressing Many of the Myths the Media is Repeating about the FDA’s Approval and Management of Mifeprex (Mifepristone)

Part Five By Randall K. O’Bannon, Ph.D., National Right to Life Director of Education & Research Editor’s note. This is the fifth and final installment in a series by Dr. O’Bannon in which he debunks seven of the many, many myths about how and why the FDA approved and managed Mifepristone. On Monday he addressed …

Continue reading "Addressing Many of the Myths the Media is Repeating about the FDA’s Approval and Management of Mifeprex (Mifepristone)"

What to make of all the talk about using misoprostol alone for abortion if mifepristone is limited

By Randall K. O’Bannon, NRL Director of Education & Research When the U.S. Food and Drug Administration (FDA) approved the abortion pill mifepristone for sale in September of 2000, it did so with a protocol that included another drug, misoprostol.  Mifepristone was taken the first day to block the pregnancy hormone progesterone and essentially starve the …

Continue reading "What to make of all the talk about using misoprostol alone for abortion if mifepristone is limited"

Addressing Many of the Myths the Media is Repeating about the FDA’s Approval and Management of Mifeprex (Mifepristone)

Part four By Randall K. O’Bannon, Ph.D., National Right to Life Director of Education & Research Editor’s note. This is the fourth in a series by Dr. O’Bannon in which he debunks seven of the many, many myths about how and why the FDA approved and managed Mifepristone. On Monday he addressed Myths 1 & …

Continue reading "Addressing Many of the Myths the Media is Repeating about the FDA’s Approval and Management of Mifeprex (Mifepristone)"

Addressing Many of the Myths the Media is Repeating about the FDA’s Approval and Management of Mifeprex (Mifepristone)

Part Three By Randall K. O’Bannon, Ph.D., National Right to Life Director of Education & Research Editor’s note. This is the third in a series by Dr. O’Bannon in which he debunks seven of the many, many myths about how and why the FDA approved and managed Mifepristone. On Monday he addressed Myths 1 & …

Continue reading "Addressing Many of the Myths the Media is Repeating about the FDA’s Approval and Management of Mifeprex (Mifepristone)"

Addressing Many of the Myths the Media is Repeating about the FDA’s Approval and Management of Mifeprex (Mifepristone)

Part Two By Randall K. O’Bannon, Ph.D., National Right to Life Director of Education & Research Editor’s note. This is the second in a series by Dr. O’Bannon in which he debunks seven of the many, many myths about how and why the FDA approved and managed Mifepristone. On Monday he addressed Myths 1 & …

Continue reading "Addressing Many of the Myths the Media is Repeating about the FDA’s Approval and Management of Mifeprex (Mifepristone)"

Addressing Many of the Myths the Media is Repeating about the FDA’s Approval and Management of Mifeprex (Mifepristone)

Part One By Randall K. O’Bannon, Ph.D., National Right to Life Director of Education & Research Since this article was originally written, Matthew Kacsmaryk, a judge from the United States District Court for the Northern District of Texas has ruled on a suit brought by the Alliance for Hippocratic Medicine and other pro-life groups challenging the 2000 approval …

Continue reading "Addressing Many of the Myths the Media is Repeating about the FDA’s Approval and Management of Mifeprex (Mifepristone)"

Addressing Many of the Myths the Media is Repeating about the FDA’s Approval and Management of Mifeprex (Mifepristone)

By Randall K. O’Bannon, Ph.D. , National Right to Life Director of Education & Research By the time you read this article, Matthew Kacsmaryk, a judge from the United States District Court for the Northern District of Texas may have already ruled on a suit brought by the Alliance for Hippocratic Medicine and other pro-life groups …

Continue reading "Addressing Many of the Myths the Media is Repeating about the FDA’s Approval and Management of Mifeprex (Mifepristone)"